Nektar Therapeutics (NKTR) Competitors $1.39 +0.02 (+1.46%) (As of 11:02 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends NKTR vs. AVIR, ADCT, MCRB, PCRX, OMER, ASMB, CPIX, AGIO, LLY, and JNJShould you be buying Nektar Therapeutics stock or one of its competitors? The main competitors of Nektar Therapeutics include Atea Pharmaceuticals (AVIR), ADC Therapeutics (ADCT), Seres Therapeutics (MCRB), Pacira BioSciences (PCRX), Omeros (OMER), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Agios Pharmaceuticals (AGIO), Eli Lilly and Company (LLY), and Johnson & Johnson (JNJ). These companies are all part of the "pharmaceutical preparations" industry. Nektar Therapeutics vs. Atea Pharmaceuticals ADC Therapeutics Seres Therapeutics Pacira BioSciences Omeros Assembly Biosciences Cumberland Pharmaceuticals Agios Pharmaceuticals Eli Lilly and Company Johnson & Johnson Nektar Therapeutics (NASDAQ:NKTR) and Atea Pharmaceuticals (NASDAQ:AVIR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, community ranking, earnings, profitability and media sentiment. Which has more volatility and risk, NKTR or AVIR? Nektar Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Comparatively, Atea Pharmaceuticals has a beta of 0.17, suggesting that its share price is 83% less volatile than the S&P 500. Is NKTR or AVIR more profitable? Atea Pharmaceuticals has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -190.09%. Atea Pharmaceuticals' return on equity of -33.24% beat Nektar Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Nektar Therapeutics-190.09% -133.64% -42.03% Atea Pharmaceuticals N/A -33.24%-31.06% Does the media refer more to NKTR or AVIR? In the previous week, Nektar Therapeutics had 13 more articles in the media than Atea Pharmaceuticals. MarketBeat recorded 16 mentions for Nektar Therapeutics and 3 mentions for Atea Pharmaceuticals. Atea Pharmaceuticals' average media sentiment score of 0.50 beat Nektar Therapeutics' score of 0.06 indicating that Atea Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nektar Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 12 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Atea Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings and valuation, NKTR or AVIR? Atea Pharmaceuticals has higher revenue and earnings than Nektar Therapeutics. Atea Pharmaceuticals is trading at a lower price-to-earnings ratio than Nektar Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNektar Therapeutics$93.16M2.71-$276.06M-$0.90-1.52Atea Pharmaceuticals$351.37M0.83-$135.96M-$2.10-1.64 Does the MarketBeat Community prefer NKTR or AVIR? Nektar Therapeutics received 612 more outperform votes than Atea Pharmaceuticals when rated by MarketBeat users. Likewise, 70.71% of users gave Nektar Therapeutics an outperform vote while only 47.37% of users gave Atea Pharmaceuticals an outperform vote. CompanyUnderperformOutperformNektar TherapeuticsOutperform Votes63070.71% Underperform Votes26129.29% Atea PharmaceuticalsOutperform Votes1847.37% Underperform Votes2052.63% Do institutionals and insiders hold more shares of NKTR or AVIR? 75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 86.7% of Atea Pharmaceuticals shares are held by institutional investors. 3.7% of Nektar Therapeutics shares are held by insiders. Comparatively, 17.8% of Atea Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Do analysts recommend NKTR or AVIR? Nektar Therapeutics presently has a consensus price target of $3.50, indicating a potential upside of 155.47%. Atea Pharmaceuticals has a consensus price target of $6.88, indicating a potential upside of 100.00%. Given Nektar Therapeutics' higher possible upside, equities research analysts clearly believe Nektar Therapeutics is more favorable than Atea Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Nektar Therapeutics 1 Sell rating(s) 2 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.43Atea Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 1 Strong Buy rating(s) 3.00 SummaryAtea Pharmaceuticals beats Nektar Therapeutics on 10 of the 19 factors compared between the two stocks. Ad Behind the MarketsThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known supplier, which provides a crucial building block for AI.Click here for the ticker >>> Get Nektar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NKTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NKTR vs. The Competition Export to ExcelMetricNektar TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$255.87M$6.87B$5.27B$8.82BDividend YieldN/A7.98%4.64%4.01%P/E Ratio-1.528.23119.9616.14Price / Sales2.71390.071,328.52102.19Price / CashN/A46.2938.8934.14Price / Book1.997.655.825.78Net Income-$276.06M$154.37M$118.30M$224.20M7 Day Performance11.38%2.27%4.08%4.17%1 Month Performance5.38%18.79%11.05%7.85%1 Year Performance174.00%42.88%39.14%28.75% Nektar Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NKTRNektar Therapeutics4.3302 of 5 stars$1.39+1.5%$3.50+151.8%+150.0%$255.87M$93.16M-1.54220Gap UpAVIRAtea Pharmaceuticals3.7851 of 5 stars$3.44-3.9%N/A+2.7%$282.81M$351.37M-1.6470Gap UpHigh Trading VolumeADCTADC Therapeutics1.945 of 5 stars$2.93-8.7%N/A+294.1%$292M$69.56M-1.15310Analyst ForecastNews CoverageMCRBSeres Therapeutics3.7495 of 5 stars$0.72-5.3%N/A-41.4%$121.73M$126.32M-0.61233Upcoming EarningsGap DownPCRXPacira BioSciences4.832 of 5 stars$17.70+0.2%N/A-41.5%$816.50M$674.98M13.51720Analyst ForecastNews CoverageOMEROmeros0.5996 of 5 stars$4.50-1.1%N/A+216.9%$260.76MN/A-1.91198Upcoming EarningsASMBAssembly Biosciences4.5091 of 5 stars$17.50+5.1%N/A+63.0%$105.65M$7.16M0.00100Gap DownCPIXCumberland Pharmaceuticals0.7478 of 5 stars$1.20flatN/A-41.5%$16.92M$39.55M-1.6480Gap UpHigh Trading VolumeAGIOAgios Pharmaceuticals3.9572 of 5 stars$55.08+6.8%N/A+137.0%$2.56B$26.82M4.85390High Trading VolumeLLYEli Lilly and Company4.9404 of 5 stars$797.58+2.7%N/A+32.8%$757.16B$34.12B86.2243,000JNJJohnson & Johnson4.9921 of 5 stars$156.71-0.7%N/A+3.8%$377.30B$85.16B22.68131,900Analyst ForecastPositive News Related Companies and Tools Related Companies AVIR Competitors ADCT Competitors MCRB Competitors PCRX Competitors OMER Competitors ASMB Competitors CPIX Competitors AGIO Competitors LLY Competitors JNJ Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NKTR) was last updated on 11/8/2024 by MarketBeat.com Staff From Our PartnersEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThe centerpiece of Trump’s crypto’s masterplan …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin...Weiss Ratings | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredThe secret supplier behind NVIDIA, Tesla and MicrosoftThe Biggest AI firms in the world...Tesla... Microsoft... NVIDIA... Are all relying on a little-known suppl...Behind the Markets | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredTrump’s Victory Just Kicked the Door Open to a…This story is about a division that has been splitting America apart at the seams for the past three and a hal...Banyan Hill Publishing | SponsoredUrgent: This election is riggedI’d like to share with you my #1 high-conviction stock to buy before Inauguration Day… and details on the asse...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nektar Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share Nektar Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NKTR Stock Alerts